Very recently, we demonstrated that low doses (10 mg/kg) of a new fenretinide formulation significantly attenuates the neurological phenotype and extends the survival of mice expressing the mutated form of human SOD1 protein (mSOD1G93A ALS mice), even when administered after the onset of motor symptoms [29]. Here, SOD1 is linked to amyotrophic lateral sclerosis.